Tuesday, October 24, 2017 10:15 PM ET
Insider Selling in Bluebird Bio (BLUE) Shares Continues
There was a substantial sale of shares of Bluebird Bio by an insider today, as indicated in a form 4 document filed with the SEC. One insider — Nick Leschly, Director and Officer — disposed of 7,050 shares in the company having a market value of approximately $1,023,268. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 11,823 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 18,873 shares and have averaged 6,291 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Bluebird Bio is greater than its 265-company peer group average. The Bio Therapeutic Drugs peer group saw 317 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by Bluebird Bio insiders is lower than its peers. Within the peer group there were 10,302,533 shares purchased and 12,445,331 shares sold with company insiders selling 6,760 shares on average over this time period.
To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data obtained to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.